Published in J Clin Endocrinol Metab on October 28, 2009
Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res (2015) 1.91
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging (2013) 1.63
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.46
Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology (2015) 1.42
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer (2014) 1.33
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab (2011) 1.19
Metastatic paraganglioma. Semin Oncol (2010) 1.12
Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf) (2013) 1.08
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer (2012) 1.05
Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc (2012) 1.04
68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med (2015) 1.02
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 0.99
15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer (2015) 0.99
Succinate dehydrogenase gene mutations in cardiac paragangliomas. Am J Cardiol (2015) 0.99
Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging (2012) 0.97
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist (2013) 0.97
MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: preliminary results. Cancer Imaging (2013) 0.95
Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res (2012) 0.94
Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res (2013) 0.90
Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab (2012) 0.89
Molecular imaging of neuroendocrine tumors. Semin Oncol (2010) 0.89
Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer (2014) 0.88
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2014) 0.88
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging (2013) 0.88
(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging (2014) 0.88
Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies? Endocr Pathol (2012) 0.87
Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med (2011) 0.87
⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging (2012) 0.85
Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res (2014) 0.85
Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics (2012) 0.84
Novel positron emission tomography tracer distinguishes normal from cancerous cells. J Biol Chem (2011) 0.83
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg (2011) 0.83
A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nat Rev Endocrinol (2011) 0.83
The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology (2014) 0.83
Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med (2013) 0.82
Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2014) 0.82
Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery (2011) 0.81
Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. Nucl Med Mol Imaging (2015) 0.81
Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nucl Med Biol (2011) 0.81
Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. J Pediatr Endocrinol Metab (2014) 0.80
Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience. Endocr Connect (2016) 0.79
Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Med Biol Eng Comput (2015) 0.79
PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2016) 0.79
Differential diagnosis of adrenal mass using imaging modality: special emphasis on f-18 fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography. Endocrinol Metab (Seoul) (2014) 0.79
Evil lurks in the heart of man: cardiac paraganglioma presenting as recurrent dyspnoea and chronic cough. BMJ Case Rep (2011) 0.79
Combined PET/CT by 18F-FDOPA, 18F-FDA, 18F-FDG, and MRI correlation on a patient with Carney triad. Clin Nucl Med (2015) 0.78
18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. J Nucl Med (2015) 0.78
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer (2016) 0.77
Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol (2012) 0.77
(18)F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. Eur J Nucl Med Mol Imaging (2016) 0.76
18F-DOPA PET/CT unravels malignant paraganglioma mimicking temporomandibular joint disorder. Dentomaxillofac Radiol (2011) 0.75
Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells. Mol Cell Endocrinol (2013) 0.75
Hypertension in a teenager: a family affair. BMJ Case Rep (2014) 0.75
Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord (2016) 0.75
Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma: Imaging With 4 Different PET Radiopharmaceuticals. Clin Nucl Med (2016) 0.75
Diagnosis: imaging of pheochromocytomas and paragangliomas. Nat Rev Endocrinol (2010) 0.75
Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. Eur J Nucl Med Mol Imaging (2013) 0.75
Targeting the de novo biosynthesis of thymidylate for the development of a PET probe for pancreatic cancer imaging. Biochemistry (2015) 0.75
Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun (2013) 0.75
(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging (2016) 0.75
Spectrum of retroperitoneal and genitourinary paraganglioma: Experience at a North Indian tertiary care center. Cent European J Urol (2015) 0.75
Nuclear medicine imaging in the evaluation of endocrine hypertension. Indian J Endocrinol Metab (2012) 0.75
Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol (2015) 0.75
N-(11)C-Methyl-Dopamine PET Imaging of Sympathetic Nerve Injury in a Swine Model of Acute Myocardial Ischemia: A Comparison with (13)N-Ammonia PET. Biomed Res Int (2016) 0.75
Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med (2017) 0.75
Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbecks Arch Surg (2017) 0.75
Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists? Br J Radiol (2017) 0.75
On the origin of cancer cells. Science (1956) 49.55
Phaeochromocytoma. Lancet (2005) 8.73
The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem (1969) 6.06
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. Radiology (2002) 1.96
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med (2007) 1.91
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab (2002) 1.84
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) (2008) 1.78
The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther (2001) 1.71
18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging (2003) 1.65
18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med (2009) 1.57
Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology (1999) 1.56
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension (2001) 1.45
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology (2001) 1.32
[11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol (2006) 1.29
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med (2008) 1.12
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med (2004) 1.12
The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol (2007) 1.11
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab (2009) 1.11
18FDG PET in oncology: the best and the worst (Review). Int J Oncol (2006) 1.09
The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol (2007) 1.05
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med (2009) 1.05
New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab (2005) 1.03
Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol (2005) 1.02
The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf) (2008) 1.01
Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology (1985) 1.01
Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis. Anticancer Res (2006) 0.99
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother (2008) 0.95
Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med (2006) 0.94
18F-DOPA PET/CT and neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2006) 0.90
A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab (2001) 0.89
Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. Eur J Surg (2001) 0.82
Phaeochromocytoma. Lancet (2005) 8.73
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab (2005) 3.32
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) (2013) 3.12
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur J Endocrinol (2014) 2.13
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab (2004) 2.00
Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab (2009) 1.98
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med (2007) 1.91
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther (2003) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J (2005) 1.80
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
Cardiovascular manifestations of phaeochromocytoma. J Hypertens (2011) 1.74
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev (2004) 1.69
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab (2004) 1.60
Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab (2002) 1.57
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol (2004) 1.56
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab (2005) 1.55
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer (2008) 1.54
Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. J Clin Endocrinol Metab (2003) 1.54
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab (2007) 1.51
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med (2007) 1.49
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2009) 1.48
Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clin Chim Acta (2013) 1.46
Increased cardiac sympathetic drive in renovascular hypertension. J Hypertens (2002) 1.46
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45